VCs back SVB as AI-native biotech fund bets on small wins

Venture capital rallies behind Silicon Valley Bank

More than 100 venture capital and investing firms signed a joint statement on Saturday supporting Silicon Valley Bank after its abrupt collapse. The signatories include heavyweights such as Sequoia Capital, General Catalyst, Kleiner Perkins, and Khosla Ventures. General Catalyst CEO Hemant Taneja posted the statement on Twitter, emphasizing that the bank has been a “trusted and long‑time partner” to the venture ecosystem for four decades.

Taneja warned that the run on the bank was “an unintended consequence of many investors trying to do the right thing for their own companies.” He argued that panic‑driven withdrawals amplified the crisis and suggested that a more measured approach—pulling out three to six months of operating capital rather than draining accounts entirely—would have mitigated the damage. The tone of the statement is conciliatory: investors will continue relationships with the institution if it is acquired by another entity, and they urge regulators to act quickly to protect depositors.

The rally is not just rhetorical. Y Combinator posted a petition signed by hundreds of founders and CEOs, demanding that the U.S. Treasury and Congress make small‑business depositors whole and tighten oversight of regional banks. Garry Tan, president of Y Combinator, called the collapse an “extinction‑level event” for startups and urged regulators to intervene. The combined pressure from VCs, incubators, and founders signals a coordinated effort to prevent a broader credit crunch in the tech sector.

Vijay Pande launches VZVC, an AI‑native biotech fund

Vijay Pande left Andreessen Horowitz’s roughly $4 billion biotech practice last year to start VZVC, an AI‑native venture fund that is dramatically smaller in size. Pande’s new vehicle focuses on applying generative AI to biology, arguing that the discipline is moving from a “discovery” science to an “engineering” one. He believes that open, shared datasets—not proprietary, walled‑off collections—will be the catalyst that finally lets AI transform medicine.

Pande’s departure from a16z underscores a broader trend: top‑down biotech investors are scaling back the number of bets they make each year. In his own words, “We’re not doing 30 bets a year.” Instead, VZVC will place a handful of deep‑tech bets, each backed by substantial computational resources and a clear path to data‑driven validation. The fund’s modest capital base forces a disciplined focus on projects that can demonstrate measurable progress early, a stark contrast to the massive, often speculative, capital deployments that have characterized biotech venture investing for the past decade.

The tension between big‑ticket bets and small, data‑driven plays

The simultaneous headlines—VCs banding together to rescue a legacy bank and a veteran biotech partner launching a lean AI‑first fund—highlight a paradox in the current venture climate. On one hand, the industry is scrambling to preserve the financial plumbing that underwrites hundreds of startups. On the other, it is rethinking how capital is allocated to emerging science.

Silicon Valley Bank’s collapse exposed the fragility of a financing model that relies on a single, specialized lender. The coordinated response shows that VCs are willing to mobilize quickly to protect that infrastructure, but it also reveals a reluctance to diversify banking relationships. Taneja’s call for “consistent approach” hints at a desire for a more resilient network of lenders, yet the statement stops short of proposing concrete alternatives.

Pande’s VZVC, by contrast, embraces a different kind of resilience: technical resilience. By betting on open datasets and AI‑driven pipelines, the fund aims to reduce the cost and time of early‑stage drug discovery, which has traditionally required massive upfront capital and long, uncertain timelines. If successful, this model could lower the barrier to entry for smaller teams and shift the venture calculus from “how much cash can we burn before a Series A?” to “how quickly can we generate predictive data that de‑risk a program.”

What the shift means for the broader innovation economy

The two stories converge on a single question: how will the venture ecosystem allocate risk in a post‑crisis environment? The SVB rally suggests that VCs will continue to protect the status quo of financing pipelines, fearing that any disruption could cascade into a talent exodus and a slowdown in startup formation. Yet Pande’s move indicates that at least some investors are willing to accept lower capital intensity in exchange for higher technical leverage.

If open, shared datasets become the norm, the competitive advantage of proprietary data hoarding will erode. That could democratize biotech R&D, allowing non‑traditional players—academic spin‑outs, smaller biotech startups, even well‑funded hobbyists—to compete on equal footing. The downside is that the value of a venture fund may shift from capital provision to platform provision, forcing VCs to double down on infrastructure, talent, and regulatory navigation.

The immediate consequence is a potential re‑balancing of power between capital and data. VCs that can curate high‑quality, interoperable datasets may become the new gatekeepers of biotech innovation, while those clinging to legacy financing models risk being left behind. The SVB episode also raises the specter of regulatory reform that could tighten capital requirements for regional banks, possibly nudging startups toward larger, more diversified banking relationships.

What to watch

Watch for three concrete developments over the next six months. First, monitor whether any major acquisition or recapitalization of Silicon Valley Bank materializes, and how quickly venture firms re‑establish credit lines for their portfolios. Second, track VZVC’s first few investments—particularly any public data releases or benchmark results that demonstrate AI‑driven hit‑rate improvements in early‑stage drug discovery. Third, keep an eye on policy proposals from the Treasury and Congress regarding deposit insurance limits and capital requirements for regional banks; any changes could reshape the financing landscape for early‑stage startups across all sectors.

These threads will reveal whether the venture community is merely patching a broken banking system or fundamentally re‑engineering how capital fuels scientific breakthroughs.

Updates

• 2026-09-14 — macOS 27: new Siri takes on AI productivity apps (source)